Novartis lung cancer drug gets EU recommendation
February 27, 2015 at 07:27 AM EST
LONDON, Feb 27 (Reuters) - European health regulators said on Friday they had recommended approval of a drug for advanced lung cancer developed by Swiss drugmaker Novartis that is intended to treat patients with a specific genetic mutation.